Description of Project

Primary objective: To determine whether a 7-day primaquine regimen is safe and not inferior to the standard 14-day regimen (total dose of 7mg/kg in both arms) in preventing P. vivax relapse in G6PD normal patients.- To assess the absolute risks and benefits of radical treatment regimens in different endemic settings. - To provide data on the safety of a weekly dose of primaquine (0.75 mg base/kg) in patients with G6PD deficiency.Secondary objectives:- To identify the most cost-effective strategies for the management of P. vivax with respect to the use of G6PD tests, the dosing schedule and the epidemiological context